The health care costs of diabetic nephropathy in the United States and the United Kingdom

References 

1. Agency for Healthcare Research and Quality . HCUPnet, healthcare cost and utilization project. Rockville, MD: Agency for Healthcare Research and Quality; 2002;
2. American Diabetes Association (2002). Available at http://www.diabetes.org/main/info/facts/impact/default2.jsp. Last checked 21 August 2002.
3. Borch-Johnsen K. The costs of nephropathy in type II diabetes. PharmacoEconomics. 1995;8:40–45
   • CrossRef
4. British Medical Association RPSoGB . In: British national formulary. London: Royal Pharmaceutical Society of Great Britain; 2002;
5. Buxton C, Gibby O, Hall M, Home P, MacKinnon M, Murphy M, et al. Diabetes information systems: a key to improving the quality of diabetes care. Diabetic Medicine. 1996;13:S122–S128
6. Centers for Disease Control and Prevention . National diabetes fact sheet: national estimates and general information on diabetes in the United States. revised ed.. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1998;
7. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2002;
8. DARTS . DARTS annual report 2001. Tayside: Tayside University Hospitals Trust; 2001;
9. Department of Health . National service framework for diabetes. London: Department of Health; 2001;
10. Department of Health . Reference costs 2001. London: Department of Health; 2002;
11. Department of Health . Departmental report 2002–3. London: Department of Health; 2002;
12. Diabetes UK . Fact sheet no. 2 — diabetes: the figures. London: Diabetes UK; 2000;
13. Drug Topics . Red book. New Jersey: Thomson Medical Economics; 2002;
14. Harvey JN, Rizvi K, Craney L, Messenger J, Shah R, Meadows PA. Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in Type 1 diabetes. Diabetic Medicine. 2001;18:998–1002
15. Hendry BM, Viberti GC, Hummel S, Bagust A, Piercy J. Modelling and costing the consequences of using an ace inhibitor to slow the progression of renal failure in type I diabetic patients. QJM. 1997;90:277–282
    • MEDLINE
    • CrossRef
16. Kernick D. Measuring the economic burden of illness. In:  Kernick D editors. Getting health economics into practice. Oxon: Radcliffe Medical Press; 2002;p. 49–54
17. McIntosh A, Hutchinson A, Marshall S, Barnes D, Brown V, Hopper S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: prevention and early management. Sheffield: ScHARR, University of Sheffield; 2002;
18. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving H, et al. Diabetic nephropathy. Diabetes Care. 2002;25:S85–S89
19. In: National Institutes of Health , National Institute of Diabetes and Digestive and Kidney Diseases  editor. Diabetes in America. 2nd ed.. Washington, DC: US Govt. Printing Office; 1995; NIH publ. no. 95-1468
20. National Kidney Federation [NKF]. Medical information from the NKF. Workshop: National Kidney Federation; 2002;
21. Office of National Statistics [ONS]. Mid-2000 UK population estimates. London: Office of National Statistics; 2002;
22. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care. 1996;19:1051–1061
    • MEDLINE
23. Scottish Intercollegiate Guidelines Network [SIGN]. Management of diabetes: a national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2001;
24. UK Transplant . UK Transplant activity report 2001. Bristol: UK Transplant; 2002;
25. US Renal Data System (2001). USRDS annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.